# US 2022/0010019 A1 · Targeting intraepithelial lymphocytes for treatment of metabolic syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0010019 A1
- Document ID: US20220010019A1
- Status: Published application
- Kind: A1
- Application number: 17/297,153
- Filed: 2019-11-26
- Published: 2022-01-13
- Earliest claimed: 2018-11-27
- Assignees: The General Hospital Corporation
- Applicants: The General Hospital Corporation
- Inventors: Filip K. Swirski; Shun He
- Web page: https://patentgrep.com/patent/US20220010019A1

## CPC

- C07K 16/2839: {against the integrin superfamily}
- A61K 38/26: Glucagons
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A61K 2039/505: {comprising antibodies}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions of treating patients with metabolic syndrome or a disease associated with metabolic syndrome using inhibitors that target natural intraepithelial lymphocytes.

## Claims

### Claim 1

A method of reducing risk of developing metabolic syndrome or a disease associated with metabolic syndrome in a subject with a family history of metabolic syndrome or a disease associated with metabolic syndrome, elevated blood pressure, dysglycemia, or abdominal obesity, the method comprising administering a therapeutically effective amount of a β7 integrin inhibitor to the subject in need thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the metabolic syndrome or the disease associated with metabolic syndrome is atherosclerosis.

### Claim 3 (depends on 1)

The method of claim 1, wherein the β7 integrin inhibitor is natalizumab or vedolizumab or etrolizumab.

### Claim 4 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the β7 integrin inhibitor is sufficient to inhibit intraepithelial lymphocyte recruitment to small intestine.

### Claim 5 (depends on 4)

The method of claim 4, wherein the β7 integrin inhibitor is delivered directly to the small intestine of the subject, e.g., intraperitoneally, subcutaneously, or by administering the β7 integrin inhibitor in an oral form that remains intact in the stomach but releases the inhibitor once in the small intestine.

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject has not been diagnosed with a metabolic syndrome or the disease associated with metabolic syndrome.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject does not have a chronic inflammatory bowel disease.

### Claim 8 (depends on 7)

The method of claim 7, wherein the chronic inflammatory bowel disease is irritable bowel syndrome, Crohn's disease, or ulcerative colitis.

### Claim 9

A method of treating a subject who has been diagnosed with metabolic syndrome or a disease associated with metabolic syndrome, the method comprising administering a therapeutically effective amount of a β7 integrin inhibitor to the subject in need thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein the metabolic syndrome or the disease associated with metabolic syndrome is atherosclerosis.

### Claim 11 (depends on 9)

The method of claim 9, wherein the β7 integrin inhibitor is natalizumab or vedolizumab or etrolizumab.

### Claim 12 (depends on 9)

The method of claim 9, wherein the therapeutically effective amount of the β7 integrin inhibitor is sufficient to inhibit intraepithelial lymphocyte recruitment to small intestine.

### Claim 13 (depends on 12)

The method of claim 12, wherein the β7 integrin inhibitor is delivered directly to the small intestine of the subject, e.g., intraperitoneally, subcutaneously, or by administering the β7 integrin inhibitor in an oral form that remains intact in the stomach but releases the inhibitor once in the small intestine.

### Claim 14 (depends on 9)

The method of claim 9, wherein the subject does not have a chronic inflammatory bowel disease.

### Claim 15 (depends on 14)

The method of claim 14, wherein the chronic inflammatory bowel disease is irritable bowel syndrome, Crohn's disease, or ulcerative colitis.

### Claim 16

A method of reducing risk of developing metabolic syndrome or a disease associated with metabolic syndrome in a subject with family history of metabolic syndrome or a disease associated with metabolic syndrome, elevated blood pressure, dysglycemia, or abdominal obesity, the method comprising administering a therapeutically effective amount of a CCR9 inhibitor or a GLP-1 agonist to the subject in need thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the metabolic syndrome or a disease associated with metabolic syndrome is atherosclerosis.

### Claim 18 (depends on 16)

The method of claim 16, wherein the CCR9 inhibitor is CCX025 or CCX282.

### Claim 19 (depends on 16)

The method of claim 16, wherein the subject has not been diagnosed with a metabolic syndrome or a disease associated with metabolic syndrome.

### Claim 20 (depends on 16)

The method of claim 16, wherein the subject does not have a chronic inflammatory bowel disease.

### Claim 21 (depends on 19)

The method of claim 19, wherein the chronic inflammatory bowel disease is irritable bowel syndrome, Crohn's disease, or ulcerative colitis.
